Showing results (21-30 of 369) with videos related to
Sort By:
Pageof 37
The Lancet. Oncology|October 3, 2009
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetYu Chen, Nicola J Clegg, Howard I ScherCurrent Opinion in Pharmacology|August 5, 2008
Targeting the androgen receptor pathway in prostate cancerYu Chen, Charles L Sawyers, Howard I ScherMedical Decision Making : an International Journal of the Society for Medical Decision Making|September 1, 2007
Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy dataGlenn Heller, Michael W Kattan, Howard I ScherSeminars in Oncology|October 23, 2003
Hsp90 as a therapeutic target in prostate cancerDavid B Solit, Howard I Scher, Neal RosenInternational Journal of Molecular Sciences|August 14, 2025
Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate CancerTatiana Erazo, Enrico Moiso, Omer Aras, et al.Urologic Oncology|March 10, 2015
Biomarker development in the context of urologic cancersGary J Kelloff, Caroline C Sigman, Howard I ScherCurrent Treatment Options in Oncology|April 25, 2012
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancerKaren A Autio, Howard I Scher, Michael J MorrisJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practiceHoward I Scher, Michael J Morris, Ethan Basch, et al.Oncology (Williston Park, N.Y.)|August 21, 2014
Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancerDiogo A Bastos, Carlos Dzik, Dana Rathkopf, et al.Cancer Journal (Sudbury, Mass.)|December 14, 2011
Circulating tumors cells as biomarkers: progress toward biomarker qualificationDaniel C Danila, Klaus Pantel, Martin Fleisher, et al.Pageof 37